Biotech · Private company

RVL Pharmaceuticals, Inc.

Track this companyFree. Adds RVL Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials80 recruiting or active

Pipeline programs7From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline7

Study of Safety and Efficacy of RVL-1201 in the Treatment of BlepharoptosisPHASE3 · COMPLETED · started Jun 28, 2018ClinicalTrials.gov NCT03565887 · fetched Nov 12, 2026
Study of Safety of RVL-1201 in Treatment of BlepharoptosisPHASE3 · COMPLETED · started Jun 20, 2018ClinicalTrials.gov NCT03536949 · fetched Nov 12, 2026
A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MSPHASE3 · COMPLETED · started Apr 3, 2018ClinicalTrials.gov NCT03319732 · fetched Nov 12, 2026
To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MSPHASE3 · WITHDRAWN · started Jul 1, 2016ClinicalTrials.gov NCT02869425 · fetched Nov 12, 2026
Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired BlepharoptosisPHASE3 · COMPLETED · started May 1, 2015ClinicalTrials.gov NCT02436759 · fetched Nov 12, 2026
Safety and Efficacy Study of RVL-1201 in Acquired BlepharoptosisPHASE1_PHASE2 · COMPLETED · started May 1, 2013ClinicalTrials.gov NCT01848041 · fetched Nov 12, 2026
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With SpasticityPHASE3 · COMPLETED · started Apr 1, 2013ClinicalTrials.gov NCT01844232 · fetched Nov 12, 2026
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple SclerosisPHASE3 · COMPLETED · started Nov 1, 2012ClinicalTrials.gov NCT01743651 · fetched Nov 12, 2026